Top

Published in:

01-02-2007 | Original Article

ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma

Authors: Yasuo Takamune, Tetsuro Ikebe, Osamu Nagano, Hideki Nakayama, Kazutoshi Ota, Takehisa Obayashi, Hideyuki Saya, Masanori Shinohara

Published in: Virchows Archiv | Issue 2/2007

Abstract

ADAM-17 (a disintegrin and metalloproteinase 17) is a membrane-anchored protein, which can cleave the ectodomain in a variety of transmembrane proteins. In the in vitro experiments with tumor cells, ADAM-17 is reported to cleave CD44, an adhesion molecule that interacts with hyaluronic acid, to promote tumor cell migration. In the present study, we examined ADAM-17 expression and CD44 cleavage in specimens from 50 patients diagnosed to have oral squamous cell carcinoma (SCC). Each specimen was divided into two pieces, one was studied by immunohistochemistry and the other was subjected to a Western blot. By coordinating the results of both analyses, ADAM-17 expression was evaluated to be high in 23 cases (46%). When CD44 cleavage was also studied by immunohistochemical staining as well as with Western blotting, CD44 cleavage was judged to be positive in 29 cases (58%). When the ADAM-17 expression level was compared with the CD44 cleavage state, most of the cases expressing high levels of ADAM-17 (87%) showed positive CD44 cleavage. The level of ADAM-17 expression was significantly correlated to the nodal metastasis and local recurrence in oral SCC. Our findings suggest that ADAM-17 is involved in CD44 cleavage and contributes to tumor progression in oral SCC.

Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729–733PubMedCrossRef

Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF (2005) Up-regulated expression of ADAM-17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207:156–163PubMedCrossRef

Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 22:1114–1124PubMedCrossRef

De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ (1998) CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. J Hered 34:162–168

Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-a-converting enzyme (TACE)/ADAM-17. J Biol Chem 280:19543–19550PubMedCrossRef

Fonseca I, Pereira T, Rosa-Santos J, Soares J (2001) Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol 76:115–120PubMedCrossRef

Gao AC, Lou W, Dong JT, Isaacs JT (1997) CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57:846–849PubMed

Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS (1994) Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54:422–426PubMed

Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153:893–904PubMedCrossRef

10.

Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK (2003) Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinoma. Int J Oncol 23:1365–1371PubMed

11.

Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer JD (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385:733–736PubMedCrossRef

12.

Nagano O, Murakami D, Hartmann D, de Strooper B, Saftig P, Iwatsubo T, Nakajima M, Shinohara M, Saya H (2004) Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca²⁺ influx and PKC activation. J Cell Biol 165:893–902PubMedCrossRef

13.

Nakamura H, Suenaga N, Taniwaki K, Matsuki H, Yonezawa K, Fujii M, Okada Y, Seiki M (2004) Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res 64:876–882PubMedCrossRef

14.

Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, Suga M, Ando M, Nakajima M, Saya H (1999) CD44 cleavage induced by membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18:1435–1446PubMedCrossRef

15.

Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441–447PubMed

16.

Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nature Rev Mol Cell Biol 4:33–45CrossRef

17.

Sato S, Miyauchi M, Takekoshi T, Zhao M, Kudo Y, Ogawa I, Kitagawa S, Fujita M, Takata T (2000) Reduced expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of tongue. Oral Oncol 36:545–549PubMedCrossRef

18.

Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteinases: multidomain proteins with multiple functions. Genes Dev 17:7–30PubMedCrossRef

19.

Sheen-Chen SM, Chen WJ, Eng HL, Sheen CC, Chou FF, Cheng YF (1999) Evaluation of the prognostic value of serum soluble CD44 in patients with breast cancer. Cancer Invest 17:581–585PubMedCrossRef

20.

Shtivelman E, Bishop J (1991) Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11:5446–5453PubMed

21.

Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H (2005) Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 11:4783–4792PubMedCrossRef

Title: ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma
Authors: Yasuo Takamune
Tetsuro Ikebe
Osamu Nagano
Hideki Nakayama
Kazutoshi Ota
Takehisa Obayashi
Hideyuki Saya
Masanori Shinohara
Publication date: 01-02-2007
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 2/2007
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-006-0350-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Sclerosing hemangioma with florid endobronchial and endobronchiolar growth

KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study

Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer

Epithelioid angiosarcoma of the bladder after irradiation for endometrioid adenocarcinoma

Primary intravascular myxoid leiomyosarcoma of the femoral vein presenting clinically as deep vein thrombosis: a case report

Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations